Problem

WhiteLab Genomics addresses the slow, expensive, and failure-prone process of developing gene, cell, and other genomic medicines. Traditional development relies heavily on laboratory trial and error: researchers form a hypothesis, test it, and return to the beginning when it fails. The result is poor efficacy, immunological side effects, substantial design complexity, and high development risk. WhiteLab cites a development path that can take up to 15 years and cost roughly $2 billion, creating pressure for therapies to become both faster and less expensive.

The central use case is helping developers choose better therapeutic candidates before committing to extensive wet-lab work. In particular, the company targets the design and selection of effective payloads, delivery vehicles, and tissue-specific vectors for gene and cell therapies, where avoiding failed experiments can materially reduce timelines, costs, and clinical risk.

Product / Service

WhiteLab provides an AI-enabled computational-biology platform and tailored solutions for biotherapy research and development. Its proprietary technology analyzes complex biological and genomic data, applies machine-learning and deep-learning methods to evaluate many hypotheses and genetic variants, and produces in-silico simulations for designing and selecting optimized therapeutic payloads and vectors. The company describes its approach as a guided rational process for identifying effective target-ligand combinations across delivery methods and tissue targets, supplemented by external wet-lab capabilities and proprietary data.

The delivery model is collaborative rather than a standalone software product only: multidisciplinary platform teams work with biotech, pharmaceutical, academic, and manufacturing partners on specific development programs. Applications include indication discovery for AAV immuno-gene therapies, optimization of AAV vectors for tissue specificity, and AI-assisted stable-cell-line and clone selection. The intended benefit is to de-risk candidate selection, shorten the path to clinical and regulatory milestones, and potentially reduce development timelines and associated costs by as much as 70% in relevant workflows.

Market

WhiteLab operates in the emerging techbio and AI-enabled genomic-medicine market, specifically computational tools and services for gene therapy, cell therapy, vector engineering, payload design, and bioproduction. Its competitive set is likely to include adjacent AI and computational-biology platforms such as Deep Genomics, which focuses on AI-driven genetic medicines and molecular-design problems, and Asimov, which offers computational and synthetic-biology tools for genetic design. These appear to be adjacent rather than proven direct substitutes, since the available evidence does not provide a formal competitor list from WhiteLab.

The company has meaningful partnership and financing traction rather than looking purely pre-revenue. Founded in 2019 and backed by Y Combinator, it announced a $10 million Series A in 2022 and reported that European and U.S. biotech and pharmaceutical companies were using its solutions for RNA, DNA, and cell-therapy programs. Subsequent collaborations include Sanofi, Cytiva, Siren Biotechnology, Genethon, INSERM, the Vision Institute, and academic partners through the €17.95 million WIDGeT consortium and €4 million GEAR project. Public evidence supports commercial and ecosystem traction, but does not establish a reliable audited revenue figure; third-party revenue estimates in the evidence are inconsistent.